A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open study to evaluate the Efficacy, Safety of Clevudine monotherapy or Adefovir and Clevudine combination in Proportion to Roadmap Concept in patients with chronic hepatitis B Associated Hepatocellular Carcinoma

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B Associated Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clevudine, Adefovir

Nucleoside-analogue naive patient : Clevudine 30mg qd

1. Assess the complete virological response(HBV DNA \< 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd
2. Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd
3. During medication of Clevudine, virological breakthrough : add adefovir 10mg qd
4. During treatment period, composite virological response : stop the medication and F/U for 2 years
5. Recurrence after stopping treatment(HBV DNA \> 2,000IU/ml) retreat medication at composite virological response.

* complete virological response: HBV DNA \< 60 IU/ml
* virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient with chronic HBV DNA and/or with symptoms of liver cirrhosis
2. Patient with Hepatocellular carcinoma evidenced by sonography, CT scan, or MRI scan)
3. Patient is 18 years and older.
4. Patient is documented to be HBsAg positive for \> 6 months.

* Laboratory report proving HBsAg positive or HBeAg positive for at least six months
* IgM anti-HBc negative, IgG anti-HBc positive at screening
5. Patient is HBV DNA positive with DNA levels ≥ 2,000 IU/mL within 30 days of baseline.
6. Patient has ALT or AST levels \>=40 IU/L
7. Cell carcinoma/hepatocellular carcinoma patient who is anticipated to live at least 1 year.
8. Patient who is fully active, able to carry on all pre-disease performance without restriction or restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
9. Patient who is classified as NYHA functional classification grade 1-2. (NYHA;New York Heart Association)
10. Patient who is able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria

1. Patient is currently receiving antiviral therapy.
2. Patients previously treated with interferon, peg-interferon or other immunomodulatory within the previous 6 months.
3. Patients previously treated with clevudine, lamivudine, adefovir, entecavir, telbivudine, tenofovir or any other investigational nucleoside for HBV infection.
4. Patient is coinfected with HCV, HDV or HIV.
5. Patient with metastatic malignancy.
6. Patient with previous liver transplantation
7. Patient is pregnant or breast-feeding.
8. Patient has a clinically relevant history of abuse of alcohol or drugs.
9. Patient use oriental medicine within the previous 2 weeks.
10. Patient has a significant immunocompromised, gastrointestinal, renal, hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone, neurological, cardiac, oncologic(except HCC)or allergic disease or medical illness that in the investigator's opinion might interfere with therapy.
11. Patient has creatinine clearance less than 60mL/min as estimated by the following formula: (140-age in years) (body weight \[kg\])/(72) (serum creatinine \[mg/dL\]) \[Note: multiply estimates by 0.85 for women\]

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bukwang

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLV-413

Identifier Type: -

Identifier Source: org_study_id